Capryloyl Salicylic Acid

The Basics On Capryloyl Salicylic Acid

What is Capryloyl Salicylic Acid?

Capryloyl salicylic acid is a derivative (ester) of salicylic acid.

What are other names for Capryloyl Salicylic Acid?

CAPRYLOYL SALICYLIC ACID

What is Capryloyl Salicylic Acid used for?

An exfoliant, anti-inflammatory and antiseptic. It’s used to treat the appearance of dry damaged skin, reducing dry patches/flaking and restoring suppleness to the skin. … For this reason, capryloyl salicylic acid is frequently used to treat blackheads, whiteheads and acne.

How Capryloyl Salicylic Acid is classified

Skin-Soothing, Exfoliant

Recommendations for using Capryloyl Salicylic Acid during pregnancy and breastfeeding

Limited data suggests no known risk

 

Capryloyl Salicylic Acid During Pregnancy

What we know about using Capryloyl Salicylic Acid while pregnant or breastfeeding

Limited information available.

AnimalDermalThe developmental toxicity of Capryloyl Salicylic Acid (in PEG-6 ) was evaluated using groups of 24 pregnant female Sprague-Dawley rats.3 The 2 test groups received doses of 40 mg/kg/day and 100 mg/kg/day, respectively, on gestation days 6 to 15. The vehicle control group was dosed with PEG-6 . The test substance and vehicle control were each applied for 6 h directly to skin on the back (not less than 10% of the body area). On gestation day 20, all females were killed and subjected to necropsy. Numbers of corpora lutea and live and dead implantations were recorded. Live fetuses were examined for external and visceral abnormalities. One-half of the fetuses were subsequently examined for skeletal abnormalities. No premature deaths or treatment-related clinical signs were recorded during the study. There was no treatment-related effect on mean maternal food consumption and body weight. However, when compared to the control group, a statistically significant reduction in body weight gain values was reported for the 40 mg/kg/day dose group (gestation days 9 Р12) and for the 100 mg/kg/day dose group (gestation days 6 Р15). There were no treatment-related effects on pregnancy parameters, mean fetal weight, and incidences of major external, visceral, or skeletal abnormalities.When compared to the background range, a higher (but not statistically significant) increase in the incidence of minor skeletal abnormalities and variants (including incomplete ossification of the sacral neural arch) was observed in the vehicle control group and both dose groups. The historical control range was from 0% to 9%, compared to a value of 18.3% for the incidence of sacral neural arch incomplete ossification in the vehicle control group. Therefore, the authors noted the likelihood that the incidence of the skeletal minor abnormalities observed in both dose groups was also overestimated. Furthermore, they noted that these statistically non-significant skeletal findings in both dose groups were likely related to the transient, but statistically significant, decrease in body weight gain observed in dams (gestation days 9 Р12). This decrease was attributed to the moderate or severe skin lesions that led to pain and stress in the animals. Therefore, it was determined that the increase in the incidence of skeletal variations reported for fetuses from both groups were likely secondary to maternal toxicity (induced by local effects leading to pain and stress) and not indicative of a teratogenic effect. Results relating to maternal skin irritation potential are included in the Skin Irritation section of this report.3 A no-observed-adverse-effect-level (NOAEL) was not reported in this study summary. However, the following conclusion is reported in a summary of this study from a different source, “ The NOAEL for developmental toxicity was established as 40 mg/kg/day, based on an increase in the incidence of fetuses with incomplete ossification of the sacral neural arch at 100 mg/kg/day.”4 The NOAEL was not established for maternal toxicity, as treatment-related effects (local reaction at the site of administration and reductions in body weight gain) were observed at both doses tested.OralThe reproductive and developmental toxicity of Capryloyl Salicylic Acid (in PEG-6 ) was evaluated using groups of 20 (10 males, 10 females per group) Wistar Hannover rats.3 The animals were dosed orally (by gavage) with the test substance once daily in accordance with OECD TG 421. The 3 dose groups received 10 mg/kg/day, 30 mg/kg/day, and 100 mg/kg/day, respectively (dose volume of 4 mL/kg/day). Male rats were dosed 2 weeks prior to mating, during the mating period, and up to 5 weeks post-mating (50 days total). Female rats were dosed 2 weeks prior to mating, during the mating period (up to 14 days), during gestation, and at least 4 additional days during the lactation period (40 to 49 days total). The vehicle control group was dosed with PEG-6 . At the end of the dosing period, all parental animals were killed and subjected to gross necropsy. Histopathological examination of tissues was performed. There were no mortalities or clinical signs that were attributed to treatment with the test substance, and there were no effects on body weight and food consumption. The following parameters in treated animals were similar to those of the vehicle control group: reproductive performance of malesand females, mating, fertility, gestation, and live birth indices. There were no treatment-related effects on weights of testes, epididymides, ovaries, uterus, and cervix. Furthermore, there were no treatment-related findings at necropsy or microscopic examination. There also were no effects on the clinical condition of pups, body weight, or sex ratio. No macroscopic findings were noted in pups that were killed on day 4 post-partum. The NOEL of Capryloyl Salicylic Acid was considered to be 100 mg/kg/day for the following: parental toxicity, embryo-fetal developmental toxicity, and pup development until day 4 post-partum.

General safety info about Capryloyl Salicylic Acid from CIR

The Cosmetic Ingredient Review (CIR) Expert Panel reviewed the safety of Capryloyl Salicylic Acid in cosmetic products; this ingredient is reported to function as a skin conditioning agent. The Panel reviewed relevant data relating to the safety of this ingredient in cosmetic formulations, and concluded that …[to be determined].

Use this, not that!

Products where you might find Capryloyl Salicylic Acid

Caudalie Vinopure Natural Salicylic Acid Pore Minimizing Serum (1 fl. oz.); La Roche-Posay Effaclar Clarifying Solution Acne Toner with Salicylic Acid (6.76 fl. oz.); La Roche-Posay Pure Vitamin C Face Serum with Salicylic Acid (1.01 fl. oz.); Farmacy HONEYMOON GLOW AHA Resurfacing Night Serum with Hydrating Honey + Gentle Flower Acids; The Ordinary Salicylic Acid 2% Masque; Peace Out Salicylic Acid Acne Treatment Serum